OncoMatch/Clinical Trials/NCT03933670
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
Is NCT03933670 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Hyperpolarized Carbon C 13 Pyruvate for prostate adenocarcinoma.
Treatment: Hyperpolarized Carbon C 13 Pyruvate — This phase II trial studies the side how well hyperpolarized carbon C 13 pyruvate (HP C-13 pyruvate) magnetic resonance imaging (MRI) works in monitoring patients with prostate cancer on active surveillance who have not received treatment. Diagnostic procedures, such as MRI, may help visualize HP C-13 pyruvate uptake and breakdown in tumor cells.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: androgen deprivation therapy (luteinizing hormone-releasing hormone (LHRH) analogue, oral anti-androgen therapy)
Exception: Previous use of a 5-alpha reductase inhibitor is allowed, provided it was discontinued at least 28 days prior to baseline C-13 HP pyruvate MRI
Current or prior androgen deprivation therapy including luteinizing hormone-releasing hormone (LHRH) analogue or oral anti-androgen therapy. Previous use of a 5-alpha reductase inhibitor is allowed, provided it was discontinued at least 28 days prior to baseline C-13 HP pyruvate MRI
Cannot have received: radiation therapy
Prior radiation treatment of the prostate
Lab requirements
Blood counts
ANC >= 1000/uL; Hemoglobin >= 9.0 g/dL; Platelets >= 75,000/uL
Kidney function
Estimated creatinine clearance >= 50 mL/min by Cockcroft Gault equation
Liver function
Total bilirubin <= 1.5 x ULN or <= 3 x ULN if known/suspected Gilbert's; AST <= 1.5 x ULN; ALT <= 1.5 x ULN
Cardiac function
No congestive heart failure with NYHA status >= 2; Poorly controlled hypertension (> 160 mm Hg systolic or > 100 mm Hg diastolic) excluded
ANC >= 1000 cells/microliter (uL). Hemoglobin >= 9.0 gm/deciliter (dL). Platelets >= 75,000 cells/uL. Estimated creatinine clearance >= 50 mL/min by the Cockcroft Gault equation. Total bilirubin <= 1.5 x ULN or <= 3 x ULN if known/suspected Gilbert's. AST <= 1.5 x ULN. ALT <= 1.5 x ULN. Poorly controlled hypertension, with blood pressure at study entry > 160 mm Hg systolic or > 100 mmg Hg diastolic. Congestive heart failure with New York Heart Association (NYHA) status >= 2.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco · San Francisco, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03933670 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior androgen deprivation therapy, radiation therapy disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages